Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocare to market Invitrogen’s breast cancer test in US

This article was originally published in Clinica

Executive Summary

Invitrogen will make its newly-approved SPOT-Light HER2 CISH test kit available in the US with the help of Concord, California-based immunohistochemistry firm Biocare Medical. The latter will have exclusive distribution rights for that market. Financial terms of the deal were not disclosed. The test received pre-market approval from the FDA to assess the breast cancer patients who could benefit from receiving Herceptin (trastuzumab) in July this year (see Clinica No 1315, p 18). According to Invitrogen (Carlsbad, California), approximately one million people globally are screened each year for HER2 gene amplification or over-expression.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041892

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel